EXHIBIT 99.1 Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026 MINNEAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the first quarter of fiscal 2026. First quarter fiscal 2026 financial and operating highlights include (with gro ...

Press Release Exhibit 99.1 Investor Contact: Charlotte McLaughlin Vice President, Investor Relations (404) 853-1456 investorrelations@acuityinc.com Media Contact: April Appling Senior Vice President, Corporate Marketing and Communications corporatecommunications@acuityinc.com Acuity Reports Fiscal 2026 First-Quarter Results Strong Performance Delivers Sales Growth, Margin Expansion and EPS Improvement ATLANTA, January 8, 2026 - Acuity Inc. (NYSE: AYI), ("Acuity"), a market-leading industrial technology comp ...

谱尼测试集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 证券代码：300887 证券简称：谱尼测试 公告编号：2025-003 1.报告期内，公司食品、环境等传统领域加强客户信用管理，对欠款超期严重客户主 动缩减合作金额；公司生物医药、新能源汽车、特殊行业检测领域建设投入比较大，市场 开拓尚需要时间，导致报告期内各类费用以及成本维持较高水平。未来公司将持续推进降 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | 比上年同期 | -25,000 | ～ | -20,000 | -35,631 | | 东的净利润 | 增长 | 43.87% | ～ | 29.84% | | | 扣除非经常性损益 | | -26,100 | ～ | - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ Form 10-Q _____________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-16583. _____ ...

财务数据关键指标变化 - 截至2025年12月31日，公司未经审计的现金、现金等价物及投资约为1.19亿美元，预计可支撑运营至2027年第二季度[6] 产品管线临床数据表现 - ACR-368在2b期注册意向试验（Arm 1，BM+患者）中，更新的中期分析显示客观缓解率为39%，在≤2线既往治疗患者中ORR为44%[11] - 在浆液性子宫内膜癌患者中，BM+患者的确认客观缓解率为67%（N=12），所有BM+和BM-患者的cORR为52%（N=23），而非浆液性患者为22%（N=37）[11] - ACR-2316的1期剂量递增研究已入组33名患者，并成功建立了两种每周口服给药方案（160 mg QD 3天用/4天停和240 mg QD 2天用/5天停）[14] - 在20名可评估患者中，有9名观察到肿瘤缩小，包括1例子宫内膜癌患者确认部分缓解，以及小细胞肺癌和鳞状非小细胞肺癌患者的未确认部分缓解[14] 产品管线研发与监管计划 - 公司计划在2026年第四季度完成ACR-368试验Arm 3的入组，设计入组最多90名患者，并可能在少至40名患者时验证临床显著性[14] - 公司预计在2026年第四季度向FDA提交ACR-6840（CDK11抑制剂）的研究性新药申请[14] - 公司计划在2026年上半年报告ACR-368试验Arm 1的更多数据和Arm 3的初步临床数据[14] - 公司计划在2026年下半年利用AP3平台启动额外的内部研发项目[17] 各地区业务拓展计划 - 公司计划在2026年第一季度在欧盟（德国、意大利、法国、西班牙）启动ACR-368试验Arm 3的入组[11][14]

Exhibit 99.1 https://files.reportify.cc/media/pro duction/LNN0c8643f0362c17545582 18135 BURKE ST. OMAHA, NE 68022 TEL: 402-829-6800 FAX: 402-829-6836 Lindsay Corporation Reports Fiscal 2026 First Quarter Results Margins remain solid despite lower revenues amid a challenging agricultural environment OMAHA, Neb., January 8, 2026 - Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, today announced results for its first quart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2026 CULLINAN THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Delaware 001-39856 81-3879991 (Commission File Number) (IRS Employer Identification No.) One Main Street Suite 1350 Cambridge, Massachusetts 02142 ( ...

Exhibit 99.1 LOGO Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights. "We are pleased by strong top-line revenue growth of PEMGARDA® (pemivibart), which we believe is attributable to our commercial execution and the fundamental appeal of monoclonal antibody prophylaxis even in the face of declining COVID vac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2026 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 001-34180 (Commission Fi ...

| GAAP | | | | | | --- | --- | --- | --- | --- | | ($ in millions, except earnings per share) | | | | | | Q4 FY25 | | | Q4 FY24 | Net Change from Q4 FY24 | | Revenue $ | 17,379 | $ | 15,845 | 9.7 % | | Gross profit $ | 1,195 | $ | 1,041 | 14.8 % | | Gross margin | 6.87 % | | 6.57 % | 30 bps | | Operating income $ | 399 | $ | 325 | 22.7 % | | Operating margin | 2.29 % | | 2.05 % | 24 bps | | Net income $ | 248 | $ | 195 | 27.5 % | | Diluted EPS $ | 3.04 | $ | 2.29 | 32.8 % | Non-GAAP Exhibit 99.1 https://fil ...